Half-year report · Q2
4544.TEDINET S100UPH6
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥120.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥236.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥116.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥956m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥821m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥7.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥821m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥291.4bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥290.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥284.6bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥155.3bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥148.3bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥136.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥142.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥150.1bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥47.0bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥39.9bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥47.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥37.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥9.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥16.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-14.47 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-132.77 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-32 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 46.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥2.5bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥76.7bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥76.5bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥205m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2.9bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥31.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥29.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥14.5bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥14.4bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥879m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥122.4bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥120.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥3.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥3.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥2.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥72.4bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥72.3bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥74m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥6.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥33.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥564m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥119.6bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥116.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 536
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)PwC Japan有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)鵜 飼 千 恵 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)添 野 俊 雄 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 116543000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 119987000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 236950000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | -1571000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | -1257000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | -7241000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | -1822000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | -821000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | -7553000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 3889000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | -2826000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | -199000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 150130000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 136080000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 142505000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 284578000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 291371000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 290849000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | -32.00 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | -14.47 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | -132.77 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.527 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.467 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.490 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 5522000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 6668000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 16551000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -7272000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -9753000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -16050000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -6055000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | 10666000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -5782000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 37096000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 47017000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 39946000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 57473822 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 57473822 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 57473822 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 57473822 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 10964400 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1916 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |